3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
20
NIH
2
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
98
Pemetrexed
70
pembrolizumab
68
Cisplatin
59
Paclitaxel
54
Docetaxel
45
Gemcitabine
37
Erlotinib Hydrochloride
24
Nivolumab
23
osimertinib
17
Bevacizumab
17
durvalumab
14
Cetuximab
13
130-nm albumin-bound paclitaxel
13
Gefitinib
11
Etoposide
11
Drug Therapy
11
Ipilimumab
9
Injections
9
Albumin-Bound Paclitaxel
9
Vinorelbine
8
Radiotherapy
8
motexafin gadolinium
7
capmatinib
7
atezolizumab
7
epacadostat
6
Taxes
6
Cyclophosphamide
6
vandetanib
5
entinostat
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Neoplasms
×
Tomography, X-Ray Computed
×
Clear all
NCT05117840
2026-04-30
SHIELD
Guardant Health, Inc.
Active not recruiting
12,000 enrolled